A method for specific quantification of hyaluronan (HA) concentration using AlphaScreen ® (Amplified Luminescent Proximity Homogeneous Assay) technology is described. Two types of hydrogel-coated and chromophore-loaded latex nanobeads are employed. The proximity of the beads in solution is detected by excitation of the donor bead leading to the production of singlet oxygen, and chemiluminescence from the acceptor bead upon exposure to singlet oxygen. In the HA assay, the donor bead is modified with streptavidin, and binds biotin-labeled HA. The acceptor bead is modified with Ni(II), and is used to bind a specific recombinant HA-binding protein (such as HABP; aggrecan G1-IGD-G2) with a His-tag. Competitive inhibition of the HA-HABP interaction by free unlabeled HA in solution is used for quantification. The assay is specific for HA, and not dependent on HA molecular mass above the decasaccharide. HA can be quantified over a concentration range of approximately 30-1600 ng/mL using 2.5 μL of sample, for a detectable mass range of approximately 0.08-4 ng HA. This sensitivity of the AlphaScreen assay is greater than existing ELISA-like methods, due to the small volume requirements. HA can be detected in biological fluids using the AlphaScreen assay, after removal of bound proteins from HA and dilution or removal of other interfering proteins and lipids.
Introduction
Hyaluronan (HA), also called hyaluronic acid, is a glycosaminoglycan composed of repeating disaccharides of β-D-glucuronic acid and N-acetyl-β-D-glucosamine. It is a major component of the extracellular matrix in many tissues. HA is synthesized by three transmembrane hyaluronan synthases: HAS1, HAS2 and HAS3 (Weigel et al. 1997; Itano and Kimata 2002; Itano 2008) . In humans, it is degraded by multiple hyaluronidases, including Hyal1, Hyal2, (also called SPAM-1), and the recently identified TMEM2 (Stern and Jedrzejas 2006; Stern et al. 2007; Yamamoto et al. 2017) . HA can be degraded by the cells with which it is associated, or released into the lymph (Tengblad et al. 1986 ). HA can then be degraded in the lymph nodes, but a small fraction is released into the blood (Laurent and Fraser 1992; Fraser et al. 1997 ). Circulating HA is rapidly taken up and digested in the liver. An increased level of serum HA is an indicator of impairment of liver function (Laurent et al. 1996) . Patients with liver cirrhosis have higher serum HA concentration than healthy human subjects, and patients with complications have higher HA concentration than those without complications (Korner et al. 1996; Crawford et al. 2009 ). Liver fibrosis, severe fibrosis and cirrhosis can be discriminated by different serum HA level cut-offs. An increased outflow of HA under inflammatory conditions can also contribute to higher circulating HA levels. For example, patients with rheumatoid arthritis have significantly higher serum HA levels than controls (Grigoreas et al. 2003; Majeed et al. 2004) . HA levels in serum or plasma can be elevated in cancer patients, and may have prognostic value (Delpech et al. 1985; Dahl and Laurent 1988; Wu et al. 2015; Peng et al. 2016) . The concentration of HA in other biological fluids also correlates with several diseases (Cowman et al. 2015a ). For example, urinary HA is a biomarker for bladder cancer; HA levels were 2.5 to 6.5-fold higher in bladder cancer patients (Lokeshwar et al. 1997 (Lokeshwar et al. , 2000 . The urinary HA level is sensitive and specific to bladder cancer, regardless of tumor grades. Thus, determination of HA concentration can reveal rich information about human disease states.
Currently, the most common method for HA quantification is enzyme-linked sorbent assay (ELSA, ELISA-like assays) (Laurent and Tengblad 1980; Tengblad 1980; Engstrom-Laurent et al. 1985; Li et al. 1989; Fosang et al. 1990 ; Kongtawelert and Ghosh 1990; Lindqvist et al. 1992; Grigoreas et al. 2003; Haserodt et al. 2011) . HA is not an antigen and does not have a specific antibody. However, HA can interact specifically with many proteins and proteoglycans, such as aggrecan, brevican, versican and link protein. These proteins have a very similar HA-binding domain (G1 domain) (Watanabe et al. 1997; Seyfried et al. 2005) . Such specific binding has been applied in many ELSA assays. Tumor necrosis factorstimulated gene 6 protein (TSG-6) is another HA-binding protein, which mediates covalent attachment of heavy chains of inter-alphainhibitor to HA. TSG-6 binds HA with relatively high affinity, but it has a separate binding site for heparin. In a previous study, TSG-6 with a mutationally inactivated heparin-binding sequence has been used for HA assay development (Jadin et al. 2014) .
The molecular mass of HA can affect its quantification. In healthy tissues, the molecular mass of HA usually averages approximately 2000-6000 kDa (Balazs et al. 1967; Laurent and Granath 1983; Dahl et al. 1985; Lee and Cowman 1994; Fraser et al. 1997; Armstrong and Bell 2002; Cowman and Matsuoka 2005) . During tissue injury and inflammation, HA can be degraded into fragments by hyaluronidases and reactive oxygen and nitrogen species (Li et al. 1997; Soltes and Kogan 2009; Schwertfeger et al. 2015; Cowman 2017) . We have previously shown that a plate-based sandwich HA ELSA fails to detect those fragments, due to strong surface attachment and consequent difficulty in probe binding for detection (Yuan et al. 2013) . Competitive ELSAs based on the formation of HA-protein complexes in solution are preferred for that reason, and can detect HA with no dependence on HA size above the minimum binding size for the detection protein.
Unfortunately, available competitive ELSA tests are less sensitive than the sandwich assays. All of the ELSA tests require multiple washing steps, which is labor-intensive and time-consuming.
Here, we report a development of a wash-free assay based on LOCI™ (Luminescent Oxygen Channeling Immunoassay) technology, which was first reported in 1994 by Ullmann and coworkers (Ullman et al. 1994 (Ullman et al. , 1996 . LOCI technology has been incorporated into modern clinical analyzer systems, such as Dimension ® Vista™ system (Siemens Healthineers, Tarrytown, NY), for a large number of diagnostic applications. It has also been licensed for research and drug discovery applications under the names AlphaScreen ® or AlphaLISA ® (Alpha = Amplified Luminescent Proximity Homogeneous Assay). In the Alpha methods, the beads are loaded with unique chromophoric groups. Donor beads are loaded with photosensitizer (phthalocyanine) that absorbs light optimally at 680 nm. In the excited triplet state, the chromophores transfer excitation to oxygen, generating singlet oxygen. Acceptor beads contain a group of chromophores that react with singlet oxygen and produce light by chemiluminescence. The wavelength of the emitted light can be shorter than that of the original 680 nm excitation of the donor beads, and depends on the chromophores used. In AlphaScreen, broad band emission is centered near 570 nm. In AlphaLISA, emission from Europium ions is narrowly centered near 620 nm (Eglen et al. 2008) . The detection of chemiluminescence requires a close physical association of the donor and acceptor beads, because the short lifetime of singlet oxygen limits its diffusion to distances of approximately 200 nm. Quantification methods based on LOCI/Alpha technology depend on suitable modification of the donor and acceptor beads to detect specific complexation. Hydrogel-coated latex beads can be modified for binding of specific species. For example, streptavidin modification allows binding of biotin-labeled species. His-tagged proteins can be bound to beads with nickel chelates on the surface. The AlphaScreen technology has been used to measure various types of molecules including signal transduction molecules (Gabriel et al. 2003; Cauchon et al. 2009 ), protein kinases (Li et al. 2003; von Leoprechting et al. 2004; Warner et al. 2004; Guenat et al. 2006) , proteases (Peppard et al. 2003) and low molecular mass glycans (Chang et al. 2011; Yegorova et al. 2013; Rodriguez et al. 2015) . One potential problem associated with application to polysaccharides is the presence of many identical available binding sites for a specific protein on a single polysaccharide molecule. The signal from a single bead pair could represent a large and variable number of protein-polysaccharide complexes, and thus not report directly on the mass of polysaccharide or number of polysaccharide chains attached or the molecular masses of the chain attached.
In the present report, an AlphaScreen assay for quantification of HA concentration has been developed, and shown to allow its sensitive analysis using as little as 2.5 μL of sample containing HA optimally in the concentration range of approximately 30-1600 ng/mL. The assay is rapid and relatively low in cost. Like ELSA methods based on competitive inhibition, quantification of HA concentration by the two-bead binding method with Alpha technology does not depend on HA molecular mass, above the minimum size needed to bind the specific protein binding partner.
Results
The design of the two-bead AlphaScreen assay for HA using competitive inhibition A schematic depiction of the HA assay design is shown in Figure 1 . AlphaScreen donor beads modified with streptavidin are able to bind biotin-labeled HA (bHA). AlphaScreen acceptor beads carrying chelated Ni +2 can bind His_HABP (recombinant human aggrecan G1-IGD-G2 carrying a C-terminal His tag). When these four components are mixed, the binding of HA to His_HABP brings donor and acceptor beads to within the 200 nm distance over which singlet oxygen ( 1 O 2 ) lifetime decays, and the close approach can be exploited in producing chemiluminescent emission at 570 nm when the donor beads are excited at 680 nm. In the presence of additional unlabeled HA binding to His_HABP, the reduction in bead complexation by competitive inhibition decreases the signal.
Optimization of reagents for binding
The assay utilized equal masses of the donor and acceptor beads, as suggested by the manufacturer. Final concentration in the assay mixture was 20 μg/mL for each. We varied the concentrations of bHA and His_HABP, in order to optimize the assay platform content. Biotinylated HA titration experiments were conducted using bHA at different final concentrations (0.37-250 ng/mL) and His_HABP at 2 μg/mL (Figure 2 ). Using a 50 kDa bHA (chosen based on its extended length of about 125 nm, which is within the 200 nm limit for singlet oxygen diffusion between beads), AlphaScreen signal increased linearly with increasing bHA-His_HABP complex formation, over the bHA concentration range of approximately 1-10 ng/mL (Figure 2A ). When bHA concentration exceeded 10 ng/mL, the curve slope decreased as the donor bead approached saturation. At concentrations greater than 90 ng/mL, the assay signal decreased ( Figure 2B ). This decrease is typical of the "hook effect" well known in immunoassays, and is caused by excess bHA being unable to bind to saturated donor beads, and the free bHA then acting to compete for His_HABP binding. Replacement of the 50 kDa bHA with longer bHA at an equimolar concentration reduced the signal ( Figure 2C ). Biotinylated HAs with higher M w , like 250 kDa and 1000 kDa, extend the distance between the donor bead and acceptor bead. Also, high molecular weight bHA chains occupy more space in solution (Cowman et al. 2015b; Cowman 2017) . As a result, fewer high molecular weight bHA chains may be attached to the donor bead, which also contributes to lower assay signal. Unless otherwise indicated below, the nearly monodisperse 50 kDa bHA was used for all studies.
His_HABP titration experiments were conducted using His_HABP at different final concentrations (62.5-2000 ng/mL) and 10 ng/mL bHA ( Figure 3) . The AlphaScreen signal increased with increasing His_HABP concentration, becoming almost saturated at 500 ng/mL. This suggested that His_HABP at a concentration of about 500-1000 ng/mL was sufficient for strong signal, and higher concentrations would give diminishing returns in signal for increases in cost of the reagent.
Optimization of the AlphaScreen competitive HA assay protocol
Protocol 1: Preformation of HA-HABP complexes before bead attachment.
In our initial attempt to develop the assay, we decided to form the HA-HABP complex first in solution prior to mixing with the donor and acceptor beads. Unlabeled Select-HA standards with molecular weights of 50 kDa, 250 kDa and 1000 kDa were tested. Unexpectedly, we found competitive inhibition of the signal was strongly dependent on the unlabeled HA molecular mass (Figure 4 ).
Whereas 1000 kDa HA strongly inhibited the signal due to twobead complexation, 250 kDa HA was less effective, and 50 kDa HA did not compete, despite the fact that the bHA molecular mass was also 50 kDa. The effectiveness of each HA size as competitive inhibitor can be expressed by the IC 50 value. IC 50 values were 5 ng/mL and 1 ng/mL for 250 kDa and 1000 kDa HA, respectively. This is slightly lower than the 10 ng/mL final concentration of the 50 kDa bHA in the assay.
Protocol 2: Preloading of bHA on donor and His_HABP on acceptor beads before competition by unlabeled HA.
Since HA is highly polydisperse in nature, an assay that can detect all molecular weight HA is preferred. In a revised protocol, we preloaded the donor beads with bHA, and the acceptor beads with His_HABP, and then donor and acceptor beads were mixed. In the absence of competitive inhibition, protocol 2 resulted in higher signal for the two-bead complexation than protocol 1. This presumably reflects the unhindered binding of labeled HA and HABP to their respective beads, which still allows them to form complexes linking the beads together. For competitive inhibition, unlabeled HA was added to the loaded donor beads holding bHA, before mixing with loaded acceptor beads. The inhibitory effects of HA of differing molecular mass were tested. At the same mass concentration, enzymatically digested and size-fractionated HA of 8-10 kDa, or Select-HA of 50 kDa, 150 kDa, 250 kDa and 1000 kDa exhibited almost the same signals ( Figure 5A ). Short HA oligosaccharides were also tested ( Figure 5B ). Decasaccharides had an inhibitory effect, but were less effective than 8-10 kDa HA. Hexasaccharides and octasaccharides could not inhibit the signal within the range of tested concentrations. The decasaccharide is reported to be the minimum HA size that can bind aggrecan with high affinity (Hardingham and Muir 1973) . In summary, the assay can be used to equally detect HA larger than decasaccharides using the preloading protocol.
Assay signal and sensitivity depend on bHA concentration
Using the optimized Protocol 2 with preloading of beads, we reexamined the impact of varying the final concentration of bHA. The final bHA concentrations in the wells were 10 ng/mL, 50 ng/mL and 250 ng/mL. Since the assay performance is independent of HA size under the precoating protocol, unlabeled Select-HA of 150 kDa was chosen as the competing standard. The concentration range was 10 ng/mL-1mg/mL. Each dilution was tested in duplicate. Results Fig. 1 . Principle of the AlphaScreen assay for HA. The donor bead is coated with streptavidin, which binds to biotin at the reducing end of bHA. The specific HAbinding protein HABP is histidine tagged at its C-terminus, and binds to a nickel-chelate coated on the acceptor bead. Upon excitation at 680 nm, the donor bead produces singlet oxygen, which diffuses to the acceptor bead. The acceptor bead subsequently emits light centered at 570 nm. Unlabeled HA competes for binding to the HABP, and reduces the signal.
are shown in Figure 6 . The initial assay signal (in the presence of a very low concentration of competing unlabeled HA) increased as bHA concentration was increased from 10 to 50 ng/mL, but then decreased at 250 ng/mL, indicating that this concentration exceeded the hooking point. This observation might favor the use of bHA at 50 ng/mL, but bHA concentration also dictates the assay midpoint location and thus its sensitivity. The IC 50 values (based on final unlabeled HA concentration in the mixture) increased from 31 to 34 to 135 ng/mL for final bHA concentrations of 10, 50 and 250 ng/ mL, respectively. Thus, the assay can better detect lower concentrations of unlabeled HA using a lower concentration of bHA. The bHA concentration of 10 ng/mL group was chosen for all subsequent studies.
Optimized standard curve
Using the optimized protocol and reagent concentrations, we developed a standard curve for signal inhibition using varying concentrations of added unlabeled HA. The signal was found to be logarithmically related to the concentration of competing HA added (and thus linearly related to the log of the HA concentration) (Figure 7) , as is typically observed in ELSA methods for HA determination. The standard HA used in this study was 150 kDa Select-HA, but since the assay was size-independent, other HA, like polydisperse 1.7 MDa HA, could also be used (Supplementary Figure 1) . Above approximately 90 ng/mL, the signal decreases due to the hook effect, reflecting the ability of excess free bHA to bind HABP on the acceptor bead and disrupt the association between beads. (C) In comparison with 50 kDa bHA, higher molecular mass bHA (250 kDa and 1000 kDa) generated lower signal at the same molar concentration. The concentration of His_HABP was 2 μg/ mL, and donor and acceptor bead concentrations were 20 μg/mL each (final concentrations). Chemiluminescent signal in counts per second (cps). The assay is appropriate for detection of HA at concentrations of about 30-1600 ng/mL. The midpoint of the standard curve is approximately 200 ng/mL (depending on exact conditions of a given assay).
Limit of blank and limit of detection
Limit of blank (LoB) and limit of detection (LoD) were estimated by measuring 12 blank wells. The apparent concentration calculated for these blank wells averaged 5 ng/mL, with a standard deviation (SD) of 8 ng/mL. Assuming a Gaussian distribution of error in signals from blank wells, LoB and LoD were calculated using the wellestablished equations: LoB = mean blank + 1.645(SD blank ), and LoD = LoB + 1.645(SD blank ) (Armbruster and Pry 2008) . LoB and LoD of the assay were thus determined to be 20 ng/mL and 30 ng/mL, respectively. This means that confidence in the assay result is low for HA concentrations below about 30 ng/mL.
Cross-reactivity
Other glycosaminoglycans, including unsulfated chondroitin, chondroitin 4-sulfate and heparan sulfate, were used to check the cross-reactivity of the assay. Even at concentrations three orders of magnitude higher than needed for HA, those glycosaminoglycans could not inhibit the assay signal, indicating that the assay is specific for HA detection (Supplementary Figure 2) .
Spike-and-recovery in DMEM
Spike-and-recovery experiments were performed to validate the assay. Exogenous HA was spiked into Dulbecco's Modified Eagle's Medium (DMEM) and tested. The AlphaScreen assay signal was artifactually reduced in DMEM, resulting in an overestimation of HA concentration in a competitive assay (Table I) . This indicates that DMEM may contain components that interfere with the assay. To reduce such interferences, DMEM was diluted 1:1 in PBS-T. The recovery rates were improved greatly in diluted DMEM, ranging from 100% to 130%. HA decasaccharide (10-mer) inhibited the assay signal, but less effectively than larger HA. HA octasaccharide (8-mer) and hexasaccharide (6-mer) could not inhibit the signal within the concentration range tested. The assay was performed in the presence of bHA at 10 ng/mL, His_HABP at 1000 ng/mL, donor and acceptor beads at 20 μg/mL each (final concentrations). Concentrations plotted are initial concentrations of unlabeled HA, in accord with convention for reporting assay data. The final concentration of unlabeled HA in the assay is 1/8th of the initial value shown in the plot. Chemiluminescent signal in counts per second (cps). Fig. 6 . Sensitivity of the AlphaScreen HA assay varies with bHA concentration used to load donor beads. The IC 50 for unlabeled HA was 31, 34 and 135 for bHA at 10, 50 and 250 ng/mL, respectively. Fig. 7 . Optimized standard curve for the AlphaScreen HA assay (protocol 2). Assay signal decreases linearly with logarithm of the HA concentration, over the range of 30-1600 ng/mL. The assay was performed in the presence of bHA at 10 ng/mL, His_HABP at 1000 ng/mL, donor and acceptor beads at 20 μg/mL each (final concentrations). Concentrations plotted are initial concentrations of unlabeled HA, in accord with convention for reporting assay data. The final concentration of unlabeled HA in the assay is 1/8th of the initial value shown in the plot. Chemiluminescent signal in counts per second (cps).
AlphaScreen assay of HA in human chondrocyteconditioned medium
The assay was applied to detect HA concentration in conditioned medium from control and interleukin 1-β (IL-1β) treated chondrocytes as a function of treatment time. Proteinase K digestion was used to liberate HA from aggrecan in the medium, and dialysis was used to remove nonspecific interference in the assay. The HA concentration in the IL-1β treated group was found to increase dramatically with time, whereas the control group showed a more modest increase in HA with time. A commercial HA ELISA (Echelon Biosciences), which is also size independent, was used as a comparison. It is important to note that removal of aggrecan by protease treatment of conditioned medium is also essential for HA detection by ELISA assays that used aggrecan HABP for detection. The result obtained by Echelon ELISA exhibited the same trend as the AlphaScreen result, but with higher values (Figure 8 ). It was reported (Haserodt et al. 2011 ) and confirmed by our lab, that the Echelon ELISA overestimates HA concentration by about 2-fold relative to the true concentration. For example, at t = 72 h, the IL-1 treated group contained about 2000/2 = 1000 ng/mL HA by ELISA, in good agreement with 1000 ng/mL HA tested by the AlphaScreen assay. Thus, the AlphaScreen assay can be applied to accurately detect HA concentration in chondrocyte-conditioned medium.
AlphaScreen assay of HA in human serum
Efforts were also made to apply this assay to detect HA in serum, since it is of great clinical interest. However, it was found that serum components had a high inhibitory effect on the assay signal, resulting in overestimation of HA concentration. Our first attempt to address this problem was to find a standard diluent that mimics the serum matrix. Standards were diluted in PBS containing 6% bovine serum albumin (BSA), then tested under the precoating protocol #2. Assay signals were too low to generate a standard curve. Thus, albumin in serum should be removed for proper assay signal. Proteinase K digestion of serum was attempted to remove albumin. After digestion, however, the serum became gel-like and white in color, probably a mixture of lipids and protein digestion products. It was very hard to collect the supernatant after centrifugation. Since HA is precipitated by ethanol (Anower-E-Khuda and Kimata 2015), it can be separated from lipids by this procedure. Therefore, HA was first ethanol precipitated, the pellet was dissolved in diH 2 O, and then protein was digested with Proteinase K. Precipitates were removed by centrifugation, the supernatant was collected and boiled to inactivate Proteinase K. After another ethanol precipitation, the pellet was reconstituted in PBS-T. When serum HA was purified by this process and tested in the AlphaScreen assay, the HA concentration was measured as 130 ± 10 ng/mL (n = 2). To confirm this value reflected only HA, purified serum was digested with recombinant bovine PH-20 hyaluronidase. Hyaluronidase was inactivated with boiling for 10 min. The HA concentration measured by AlphaScreen after hyaluronidase digestion was below the detection limit.
Alternative binding proteins
Other HA-binding proteins including tumor necrosis factorstimulated gene 6 protein (TSG-6) and link protein were checked as alternative binding proteins. Under a competitive test protocol using PBS with 0.1% BSA in place of PBS-T, 1 μg/mL His_TSG-6 or His_Link were used instead of His_HABP. When His_Link was used, the smallest size that was detected was decasaccharide, which is the same as HABP (Supplementary Figure 3) . When TSG-6 was used, HA 50 kDa or larger was properly detected, but 8-10 kDa HA was inadequately detected (Supplementary Figure 4) . We also tested TLR2, TLR4, and a complex of TLR4 with MD-2. These proteins The apparent HA concentration in a competitive assay can be overestimated unless interfering substances are sufficiently diluted. Fig. 8 . Comparison of the AlphaScreen HA assay and a commercial competitive ELISA assay for HA concentration in chondrocyte-conditioned medium. Cells were serum starved and treated in the presence or absence of IL-1β inflammatory stimulus for increasing periods of time. Results were in good agreement, after consideration of the reported nearly 2-fold overestimation of HA by the commercial assay.
showed no evidence of binding to the 50 kDa bHA, and thus were not useful in HA detection.
Alternative biotinylated HA
To ensure the future availability of a key reagent for the assay, we tested bHA prepared by reductive amination of unlabeled HA, using Biotin-LC-hydrazide (Supplementary Figure 5) . Excess free biotin was removed using a spin desalting column. No degradation of HA was observed in the biotinylation process. On average, 1.2 ± 0.3 biotin molecules were incorporated per HA chain, in accord with expectation. The chemically end-labeled bHA exhibited very similar affinity to the commercially available bHA (Supplementary Figure 6) .
Discussion
A bead-based assay for the specific detection of HA concentrations using AlphaScreen and LOCI energy transfer technology was developed. The assay signal is dependent on bead proximity, driven by the association between streptavidin-coated donor beads carrying biotinylated HA and nickel-chelate-coated acceptor beads carrying His-tagged HABP (aggrecan G1-IGD-G2). Changes in assay signal due to competitive inhibition by unlabeled HA allow quantification of free HA. The AlphaScreen assay is highly sensitive, requiring HA samples to be in the concentration range of approximately 30-1600 ng/mL, but using only 2.5 μL of sample. Thus the mass of HA needed for quantification is only 0.08-4 ng. The assay is not dependent on HA size above the decasaccharide, but smaller oligosaccharides cannot bind the specific HABP, and therefore cannot be detected. The assay does not have cross-reactivity with unsulfated chondroitin, chondroitin 4-sulfate or heparan sulfate. The assay can be applied to measure the concentration of purified HA, or HA in cell culture conditioned medium or serum, but requires predigestion of HA-bound proteins or proteoglycans, and/or reduction or removal of co-dissolved serum proteins and lipids if present at high concentration.
In comparison with currently available competitive ELISA-type assays, the AlphaScreen assay is more sensitive, because it covers a similar concentration range but uses only 2.5 μL of the sample versus 100 μL in standard ELISAs. Relative to sandwich ELISA assays, the AlphaScreen assay provides results that are independent of HA size above the decasaccharide, whereas the sandwich ELISAs severely underestimate HA with molecular mass less than about 150 kDa.
The homogenous assay is performed entirely in the aqueous environment at the hydrogel surface of small latex beads, rather than at the surface of a plastic plate. There are no washing or separation steps that could result in exposure of surfaces to air. The entire assay procedure requires about 5 h.
The assay is perhaps unexpectedly successful, because a polysaccharide like HA has many potential binding sites for a protein like HABP. Thus, the signal arising from complexation of donor and acceptor beads loaded with bHA and His_HABP, respectively, is likely to reflect a large number of simultaneous binding events linking the beads. Added unlabeled HA must compete for this interaction by occupying an equivalently large number of HABP molecules, possibly in close proximity to each other, and this should preferably not depend on the length of the HA molecule.
Using a default protocol often used with protein immunoassays (preformation of the HA-protein complexes before bead attachment), the detection of HA was indeed found to depend on its molecular mass. Since the binding of HABP to HA is not known to be cooperative, it is not expected that the HABP preferentially binds to higher molecular mass HA during the pre-incubation. The experimental observations may instead suggest that the affinity of a preformed complex of HA with HABP for an acceptor bead can depend on the total number of HABP in the complex, and thus on the HA molecular mass and on the total number of His-tagged HABP interactions with the chelated Ni surface coating of the bead (Supplementary Figure 7) . Precomplexed HABP may also be generally less accessible to the acceptor beads, due to conformational constraints arising from the known helical arrangement of HABP along HA chains.
In the optimized protocol, the separate preloading of donor and acceptor beads allows unlabeled HA to compete freely for binding to the acceptor bead surface, and the binding is independent of HA molecular mass. This modification of the method made assay of polydisperse HA in biological samples accessible. Unlabeled HA of different sizes maintains a constant ratio of protein bound per unit of HA mass, as dictated by the arrangement of HABP on the surface of the bead, and effectively competes with the biotinylated HA by virtue of the number of HABP left unbound by unlabeled HA (Supplementary Figure 8) .
We found that His-tagged cartilage link protein and TSG-6 can be used as alternative binding proteins, when His_HABP is not applicable. For example, His_HABP cannot be used when a sample contains aggrecanases such as ADAMTS-4 (Tortorella et al. 1999) or ADAMTS-5 (Glasson et al. 2005) . HABP is the G1-IGD-G2 domain of aggrecan, and the IGD domain is a major aggrecanase cleavage site (Little et al. 2007) . HA binds to the G1 domain of HABP, which is also His-tagged at the G2 domain. Cleavage in the IGD domain would dissociate the HABP G1 from the acceptor beads and inhibit the assay signal. In addition to alternate choices of binding proteins, other modes of HA or binding protein attachment to the donor and acceptor beads could potentially be advantageous for specific applications. Beads with many different surface modifications are commercially available.
AlphaScreen methods are generally applicable to the study of GAG-protein, or other oligo/poly-saccharide-protein interactions, with due consideration for specific structural requirements. Using AlphaScreen, we were unable, however, to detect the binding of 50 kDa bHA to the TLR receptor proteins TLR2, TLR4, or a mixture of TLR4 and MD2. This failure may be attributable to the HA size used in our assay. Especially, it is possible that only HA with a size less than 50 kDa is able to bind to the TLR receptors.
In summary, we have developed a novel AlphaScreen assay to determine the concentration of HA. This assay accurately determines the concentration of HA and is not dependent on HA molecular size above the decasaccharide. The newly developed method requires a microplate reader with the capability for pulsed laser excitation at 680 nm, and time-delayed detection of chemiluminescence near 570 nm. The major advantages of our newly developed AlphaScreen assay are the low cost per test compared to commercially available ELISA kit. Another advantage is the option to use 384-well plates for high throughput analyses.
Materials and methods

Materials
Chemoenzymatically synthesized HA samples with narrow size distribution and known average molecular mass determined by size exclusion chromatography with multiangle light scattering (Select-HA™, having nominal average HA molecular masses of 1000 kDa, 250 kDa, 150 kDa, 50 kDa, 30 kDa) were obtained from Hyalose LLC (Austin, TX). Biotin end-labeled 50 kDa hyaluronan (SelectHA™ 50 K), hereafter called bHA, was obtained from Hyalose LLC. A low molecular mass HA sample containing chains 19-25 disaccharides in length (8-10 kDa) was prepared as previously described (Turner et al. 1988 ). Even-numbered HA oligosaccharides with reducing end N-acetyl-D-glucosamine were obtained from Hyalose LLC (10-mer) and from Contipro (6-mer, 8-mer). Polydisperse high molecular mass HA was purchased from Lifecore Biomedical (Chaska, MN) . Chondroitin 4-sulfate was purchased from Seikagaku Corporation (Tokyo, Japan). Unsulfated chondroitin was provided by Dr. Paul DeAngelis (University of Oklahoma Health Sciences Center). Heparan sulfate was purchased from Sigma Aldrich (Cat# H7640). Recombinant histidine-tagged proteins, including Aggrecan G1-IGD-G2 domain (HA-binding protein), TSG-6, Link protein, TLR2, TLR4, complex of TLR4 with MD-2 and PH-20 were purchased from R&D Systems Inc. The competitive HA ELISA kit K-1200 was purchased from Echelon Biosciences. Proteinase K was purchased from Roche Diagnostic. PBS (0.01 M phosphate, 0.138 M NaCl, 0.0027 M KCl, pH 7.4; catalog #P3813) and PBS-T (PBS containing 0.05% Tween 20; catalog #P3563) were obtained from Sigma Chemical Co. DMEM high glucose culture medium was obtained from Life Technologies. Fetal bovine serum was obtained from Atlanta Biologicals. Human serum was obtained from MP Biomedical (Cat# 0, 929, 309) . Streptavidin-labeled donor beads and Ni chelate-labeled acceptor beads for AlphaScreen assays were obtained as a set from Perkin Elmer (#6,760,619C). Beads were supplied as suspensions containing 5000 μg/mL, and were stored at 4°C. Other chemical reagents were purchased from Sigma Aldrich (St. Louis, MO). Slide-A-Lyzer MINI Dialysis Devices (3.5 K MWCO, 2 mL), Zeba™ Spin Desalting Column (7 K MWCO, 0.5 mL), Maxi Strong Anion Exchange Spin Column, Pierce™ EZ-Link-Biotin and Pierce Biotin Quantitation Kit were purchased from ThermoFisher Scientific (Waltham, MA). Filters with 0.2 μm pore size were from Pall Corporation. Half-size 96 well opaque white microplates were obtained from Perkin Elmer.
Reagent reconstitution and storage
Biotinylated HA (bHA) from Hyalose LLC was dissolved in deionized water at a concentration of 200 μg/mL, and stored at 4°C. Prior to use, an aliquot was diluted to 1 μg/mL with filtered PBS-T.
Unlabeled HA samples and other glycosaminoglycans were dissolved in deionized water at 1000 μg/mL, stored at 4°C, and aliquots were diluted to 10 μg/mL with filtered PBS-T before use. Proteins were dissolved in 0.2 μm filtered PBS at a concentration of 100 μg/ mL, and stored at −20°C in 20 μL aliquots.
Beads suspensions were handled and loaded under dim light with a green filter (Roscolux Chroma Green #389), and kept protected from light using aluminum foil during incubation steps. All assay reagents were pre-equilibrated and all procedures were performed at room temperature. (Variation in temperature can have a significant effect on the signal amplitude.) All incubations were performed with gentle orbital shaking.
Instrumental methods and data analysis
AlphaScreen assay plates were read on a Molecular Devices (Sunnyvale, CA) SpectraMax ® i3 Multi-Mode Microplate Detection Platform using a SpectraMax ® AlphaScreen 384 STD Detection
Cartridge with excitation wavelength of 680 nm and emission filter for 570 nm with 100 nm bandwidth. Temperature was 21-22°C.
Excitation time was 140 ms and integration time was 280 ms. Data were collected with SoftMax Pro 6.4 (Molecular Devices) and analyzed with GraphPad Prism 6 (GraphPad Software, La Jolla, CA). Concentrations of standards (X values) were transformed using X = Log(X), then plotted data using 4-parameter nonlinear regression. In accord with convention for quantification assays, graphs for experiments in which unlabeled HA is detected are plotted using the initial concentration of unlabeled sample HA before addition to the assay mixture. Final concentration in the assay is 1/8th of the initial value.
Optimization of bHA concentration for assay Reagent dilutions. A 1000 ng/mL solution of bHA in PBS-T was serially diluted to 360, 120, 40, 13.3, 4 .4 and 1.48 ng/mL with PBS-T. His_HABP was diluted from 100 μg/mL in PBS to 8 μg/mL with PBS-T. AlphaScreen bead suspensions supplied at 5000 μg/mL were spun down for a few seconds, then mixed gently by pipetting. An aliquot was diluted to 80 μg/mL with PBS-T. Assay method. Biotinylated HA of 5 μL was mixed with 5 μL His_HABP in ½ area 96-well microplate, then sealed with a plate sealer. The plate was incubated for 2 h at room temperature. After adding 5 μL acceptor bead, the plate was incubated for 1 h. Finally, 5 μL donor bead was added under subdued green light. Then the plate was incubated for 1 h in black box. The plate was read using AlphaScreen detection. Final concentrations of bHA were 250, 90, 30, 10, 3.3, 1.1 and 0.37 ng/mL. Final concentrations of His_HABP and beads were 2 μg/mL and 20 μg/mL each, respectively.
Optimization of His_HABP concentration for assay
Reagent dilutions: His_HABP at 100 μg/mL in PBS was diluted to 8000, 4000, 2000, 1000, 500 and 250 ng/mL with PBS-T. The 1000 ng/mL bHA stock solution was diluted to 40 ng/mL with PBS-T.
Assay method. Steps were the same as above. Final concentrations of His_HABP were 2000, 1000, 500, 250, 125 and 62.5 ng/ mL. Final concentrations of bHA and beads were 10 ng/mL and 20 μg/mL each, respectively.
Competitive assay procedure. Protocol 1 Reagent dilutions. Unlabeled HA standards (50 kDa, 250 kDa and 1000 kDa) were diluted to 800, 267, 80, 24, 8, 0.8, 0 .08 ng/mL with PBS-T. Biotinylated HA (bHA) was diluted to 80 ng/mL with PBS-T. His_HABP was diluted to 8 μg/mL with PBS-T. Beads were diluted to 80 μg/mL with PBS-T.
Assay method. HA standards 2.5 μL were mixed with 2.5 μL bHA in ½ area 96-well microplate for 30 min. Then 5 μL His_HABP was added. The plate was sealed and incubated for 2 h. After adding 5 μL acceptor bead, the plate was incubated for 1 h. Finally, 5 μL donor bead was added. The plate was read after incubation for 1 h in black box. Final concentrations of bHA, His_HABP and beads were 10 ng/mL, 2 μg/mL and 20 μg/mL each, respectively. The final concentrations of unlabeled HA in the assay mixture were 0.01-100 ng/mL, for initial sample concentrations of 0.08-800 ng/mL.
Competitive assay procedure. Protocol 2 (optimized protocol)
Reagent dilutions. Unlabeled HA standards (6-Mer, 8-Mer, 10-Mer, 8-10 kDa, 50 kDa, 150 kDa, 250 kDa and 1000 kDa) were diluted to 8000, 2667, 889, 296, 99, 33, 11 and 3.66 ng/mL with PBS-T.
Use bHA at 1 μg/mL in PBS-T. Use His_HABP at 100 μg/mL in PBS. Use beads at 5000 μg/mL, as supplied.
Assay method. In this protocol, donor and acceptor beads were separately preloaded with their respective binding partners before mixing together in the presence of unlabeled HA sample. In a 1.5 mL microcentrifuge tube, mix 24 μL bHA with 9.6 μL donor bead stock solution, then add PBS-T to 900 μL. In another 1.5 mL tube, mix 24 μL His_HABP stock solution with 9.6 μL acceptor bead, add PBS-T to 1200 μL. Incubate both tubes for 1 h, in black box. After 45 min of the bead incubation time, HA standards and samples were added to the microplate, using 2.5 μL/well. This process took about 15 min. Then under subdued green light, 7.5 μL bHA coated donor bead was added to each well. The plate was sealed and incubated for 30 min in the dark, then 10 μL His_HABP coated acceptor bead was added to each well. The plate was covered with a plate sealer and protected from light with aluminum foil. It was incubated 2 h. Read the plate. In the final 20 μL volume, the assay contained 20 μg/mL for each bead type, 1 μg/mL His_HABP and 10 ng/mL bHA. Final concentrations of HA standards were 1000, 333, 111, 37, 12, 4, 1.3, 0.46 ng/mL.
Standard curve
The standard curve of the optimized assay used Protocol 2 with an HA standard of 150 kDa at dilutions of 1600, 800, 400, 200, 100, 50 and 25 ng/mL in PBS-T. Final concentrations of HA standards in the assay mixtures were thus 200, 100, 50, 25, 12.5, 6.25 and 3.125 ng/mL.
Cross-reactivity
Other GAGs, including unsulfated chondroitin, chondroitin 4-sulfate and heparan sulfate were tested at dilutions of 500 μg/mL, 50 μg/mL, 5 μg/mL, 500 ng/mL, 50 ng/mL and 5 ng/mL in PBS-T. Other steps were the same as protocol 2. Final concentrations of GAGs were 62.5 μg/mL, 6.25 μg/mL, 625 ng/mL, 62.5 ng/mL, 6.25 ng/mL and 0.625 ng/mL.
Alternative binding proteins
His_TSG-6 and His_Link were tested as HA-binding proteins instead of His_HABP. Following the revised competitive protocol, unlabeled HA of various molecular masses were tested. For these HA-binding proteins, the standard curves showed poor shape and reproducibility. We found that replacing PBS-T buffer with PBS containing 0.1% (w/v) bovine serum albumin (BSA) improved the assay for those proteins. His_TLR2, His_TLR4 and His_TLR4 in complex with His_ MD-2 were studied in PBS-T.
Purification of HA from chondrocyte-conditioned medium
Human articular chondrocytes were grown to confluence in DMEM containing 10% fetal bovine serum until cells were confluent. Cells were then serum starved for 24 h before treatment with 10 ng/mL human recombinant interleukin-1 beta (IL-1β) in PBS/0.1%BSA or PBS/0.1%BSA (vehicle) for up to 72 h. Medium was collected at the time points indicated. HA in the medium was purified by overnight dialysis to 0.1 M NaCl, followed by overnight digestion at 60°C with 475 μg/mL proteinase K, and boiling for 15-20 min to inactivate the protease. The liberated HA was subjected to assay by AlphaScreen Protocol 2. As a comparison, samples were also tested using a commercial competitive ELISA for HA (Echelon Biosciences), following kit instructions.
Purification of HA from serum
Ethanol containing 1.3% (w/v) sodium acetate (ethanol/NaAc) was pre-chilled at 4°C. Serum sample (100 μL) was mixed with three volumes of cold ethanol/NaAc. After vortexing, the mixture was kept on ice for 30 min, then centrifuged at 12,000 × g for 20 min at 4°C. The pellet was reconstituted in 400 μL diH 2 O. Precipitation with three volumes of ethanol/NaAc was repeated three times. The pellet was dissolved in 400 μL digestion solution containing 3 mg/ mL proteinase K and 10 mM CaCl 2 . After overnight digestion at 50°C, proteinase K was inactivated by boiling for 15 min. The sample was precipitated as above with three volumes of ethanol/NaAc for three more times, and the pellet was finally dissolved in 100 μL PBS-T.
Fractionation of polydisperse HA by ion exchange chromatography
Polydisperse Lifecore HA was fractionated by ion exchange chromatography as previously reported (Yuan et al. 2015) . Briefly, 1 mg 22 kDa Lifecore HA and 1 mg 112 kDa Lifecore HA were dissolved in 10 mL 0.1 M NaCl solution. The Maxi anion exchange spin column was pre-washed with 5 mL 0.1 M NaCl once, 5 mL 0.8 M NaCl for three times and 5 mL 0.1 M NaCl for five times. For each washing step the column was centrifuged at 400 × g for 2-3 min. Then the column was loaded with 10 mL HA solution and centrifuged at 400 × g for 5 min. The column was washed once with 5 mL 0.1 M NaCl and three times with 5 mL 0.2 M NaCl. To elute HA of increasing size, the column was eluted stepwise with 2 × 2 mL aliquots of NaCl solutions with concentrations of 0.300, 0.330, 0.360, 0.400, 0.416, 0.440 and 0.800 M. The 0.440 M fraction was precipitated with ethanol and reconstituted with diH 2 O. The M n was determined by polyacrylamide gel electrophoresis.
Biotinylation of HA via reducing end
Hydrazide-LC-biotin was dissolved in 15% acetic acid at 7.6 mM with heat and vigorous shaking. A 50 μg aliquot of 0.44 M NaCl HA fraction (M n = 86 kDa) was dried and re-dissolved with 20 μL acidic biotin solution. After incubation for 15 min at 60°C, 5 μL of 1 M sodium cyanoborohydride solution was added. After overnight incubation at 60°C, the solution was diluted to 100 μL with diH 2 O. The solution was then applied to a 7 K MWCO desalting spin column following the instruction from the manufacturer. The desalting step was repeated once with a new desalting column. The collected solution was stored at −20°C. The biotinylation level was determined by comparing the molar concentration of biotin with the molar concentration of HA molecule. Biotin concentration was estimated with the Pierce biotin quantitation kit.
Supplementary data
Supplementary data is available at Glycobiology online. 
